A ‘new drug’ holds the foremost value of the pharmaceutical industry. And global pharmaceutical companies’ eyes are currently fixated on the ‘adequate value of new drug’ than ever before.

As the era of high-cost drug has come, government and pharmaceutical industry’s gap in views of drug pricing has never been so apart. Korea Research-based Pharmaceutical Industry Association (KRPIA), representing the voices of global pharmaceutical companies in Korea, is stepping forward seeking the middle ground of the two.

A consensus between them does exist. For an instance in last year, the Korean health authority expanded scope for risk sharing agreement (RSA) and announced a plan to apply RSA